Challenge of managing cancer-related fatigue

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages 3671-3672

  Bruera, Eduardo ^a   Yennurajalingam, Sriram ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT;

ANOREXIA; ATTENTION DEFICIT DISORDER; BODY COMPOSITION; BRAIN FUNCTION; CANCER FATIGUE; CANCER PATIENT; DISEASE COURSE; DISEASE SEVERITY; DRUG RELEASE; EDITORIAL; HUMAN; NERVOUSNESS; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE; FATIGUE; NEOPLASM; NOTE; PATHOPHYSIOLOGY;

CENTRAL NERVOUS SYSTEM STIMULANTS; FATIGUE; HUMANS; METHYLPHENIDATE; NEOPLASMS;

EID: 77957266013     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.8984     Document Type: Editorial

References (13)

1. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5:353-360, 2000
2. National Comprehensive Cancer Network: Cancer-related fatigue panel 2006 guidelines. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
3. Lawrence DP, Kupelnick B, Miller K, et al: Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:40-50, 2004
4. Minton O, Richardson A, Sharpe M, et al: A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 100:1155-1166, 2008
5. Seruga B, Zhang H, Bernstein LJ, et al: Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887-899, 2008
6. Yennurajalingam S, Bruera E: Palliative management of fatigue at the close of life: "It feels like my body is just worn out." JAMA 297:295-304, 2007
7. Moraska AR, Sood A, Dakhil SR, et al: Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: NCCTG Trial NO5C7. J Clin Oncol 28:3673-3679, 2010
8. Yennurajalingam S, Palmer JL, Li Z, et al: Factors associated with response to methylphenidate in advanced cancer patients with cancer-related fatigue. J Clin Oncol 28:637s, 2010 (suppl; abstr 43655)
9. Bruera E, Valero V, Driver L, et al: Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial. J Clin Oncol 24:2073-2078, 2006 (Pubitemid 46622117)
10. Peterson K, McDonagh MS, Fu R: Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: A systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 197:1-11, 2008
11. Bruera E, Fainsinger R, MacEachern T, et al: The use of methylphenidate in patients with incident cancer pain receiving regular opiates - A preliminary report. Pain 50:75-77, 1992
12. Homsi J, Nelson KA, Sarhill N, et al: A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 18:403-407, 2001
13. Butler JM Jr, Case LD, Atkins J, et al: A phase III, double-blind, placebocontrolled prospective randomized clinical trial of d-threo- methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 69:1496-1501, 2007 (Pubitemid 350116415)